NCT01106599View on ClinicalTrials.gov

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Solid Cancers
Interventions
DRUG

GDC-0623

Repeating oral dose

Trial Locations (4)

37203

Nashville

73104

Oklahoma City

90033

Los Angeles

95817

Sacramento

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY